Shots:
- Mabwell has dosed the first patient with 9MW3811 in its P-II (CTR20254857) trial in China for pathological scarring
- The trial will assess safety, tolerability, PK, & preliminary efficacy of 9MW3811 in pts with pathological scarring following P-I completion in healthy subjects across Australia & China
- 9MW3811 has shown significant preclinical efficacy in pulmonary fibrosis models & demonstrated potential across fibrosis-related diseases, incl. hypertrophic scars & abnormal endometrial bleeding, plus reduced fibrosis & scar volume in human-derived keloid models
Ref: PRnewswire | Image: Mabwell | Press Release
Related News: Mabwell Receives the US FDA IND Clearance to Initiate P-IIa Trial of 9MW1911 in COPD
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
